Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR001 in advanced solid tumors
NCT06134531Phase 1Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MR001 in solid tumor, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events at 12 months and Dose Limited Toxicity (DLT) and Maximum Tolerated Dose (MTD) at 12 months. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
MR001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06134531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134531.